Almenar-Pérez, Eloy, Sánchez-Fito, Teresa, Ovejero, Tamara et al. · Pharmaceutics · 2019 · DOI
This study looked at how medicines commonly taken by fibromyalgia and ME/CFS patients might interfere with blood tests that could help diagnose these conditions. The researchers found that many prescription drugs can affect small molecules in the body called microRNAs, which are being studied as potential diagnostic markers. This means that when researchers try to identify disease-specific biomarkers, they may be picking up drug effects instead of actual disease signatures.
This research highlights a critical and previously underappreciated barrier to developing reliable diagnostic tests for ME/CFS: the confounding effects of medications that most patients take. Understanding how drugs mask true disease biomarkers could accelerate the discovery of valid diagnostic markers and enable more personalized treatment approaches for ME/CFS patients. It also raises awareness that miRNA profiles could eventually help doctors choose safer, more effective medications tailored to individual patients.
This study does not prove that any specific drug definitively causes false biomarker results in individual ME/CFS patients, nor does it demonstrate that validated diagnostic biomarkers will become available once drug effects are controlled for. It is a literature review identifying potential interactions rather than an experimental study measuring actual biomarker changes in patients. The findings are associational and do not establish the clinical magnitude or reversibility of drug-induced miRNA alterations.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Almenar-Pérez, Eloy, Sánchez-Fito, Teresa, Ovejero, Tamara, Nathanson, Lubov, & Oltra, Elisa (2019). Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments.. Pharmaceutics. https://doi.org/10.3390/pharmaceutics11030126
BibTeX
@article{mecfsatlas-almenar-prez-2019-impact-polypharmacy,
author = {Almenar-Pérez, Eloy and Sánchez-Fito, Teresa and Ovejero, Tamara and Nathanson, Lubov and Oltra, Elisa},
title = {Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments.},
journal = {Pharmaceutics},
year = {2019},
doi = {10.3390/pharmaceutics11030126},
note = {PubMed: 30889846},
url = {https://www.mecfsatlas.com/evidence/almenar-prez-2019-impact-polypharmacy},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-05-30. https://www.mecfsatlas.com/evidence/almenar-prez-2019-impact-polypharmacy
Contribute
Private, reviewed by a human. Not a public comment thread.